Use objective biological data to tailor patient care.

Encompass™ replaces maternal characteristics and broad demographics with objective biology to predict risk.

Tailor care for your patients based on their risk with breakthrough RNA-science.

Use objective biological data to tailor patient care.

Encompass™ replaces maternal characteristics and broad demographics with objective biology to predict risk.

Tailor care for your patients based on their risk with breakthrough RNA-science.

Current preeclampsia guidelines are failing pregnant moms.

After nearly a decade of revised clinical recommendations, the condition is increasingly common and more severe.

Preeclampsia rate

Rate has doubled since 2008.

Severity of cases

Most cases are classified as severe.

TODAY

Relying on maternal characteristics and broad demographics leaves a critical clinical gap that is failing the majority of pregnant moms and their care teams. A study published in JAMA of 5,684 participants found that current USPSTF and ACOG guidelines identify 89% of pregnancies as having an increased risk of preeclampsia, resulting in a one size fits all approach that has proven to be ineffective.

Simple, RNA-based blood test. Validated with superior, unbiased performance.

Encompass uses breakthrough RNA science to identify elevated-risk patients and motivates them to comply with a preventive action plan to reduce their risk.

The test performs equally across race and ethnicity – replacing demographics with objective biology. The scientific foundation includes a prospective, 9,102-pregnancy, multi-center clinical validation study published in Nature Communications. Powered by the Mirvie RNA Platform, Encompass reads thousands of signals from the mother, baby, and placenta to deliver unmatched predictive insight

Available now for most advanced maternal age pregnancies.

How to order

Find the right patient. Activate the right care. Reduce preeclampsia risk.

Encompass simplifies risk stratification so you can focus on personalizing their care before preeclampsia becomes a crisis.

Powerful data to drive compliance to your evidence-based care plan to reduce their risk.

Provides greater confidence to personalize prenatal care for patients at very low risk.

Elevated-risk patients are more adherent to low-dose aspirin.

Objective risk results motivate the right behavior change. Prospectively collected, multicenter, real-world evidence shows that 93% of elevated-risk patients adhere to low-dose aspirin at the frequency proven effective in randomized controlled trials.

Low-dose aspirin adherence

Encompass lifts adherence
from under 10% to over 90%.

Available now for most advanced maternal age pregnancies.

How to order

THE NEXT GENERATION OF PREGNANCY CARE IS HERE

Encompass simplifies risk stratification to tailor patient care.

"Patients should know their preeclampsia risk before it becomes a crisis. The prenatal care model - designed nearly 100 years ago to manage preeclampsia - has remained largely unchanged. Encompass is a paradigm shift based on an increased understanding of the underlying biology of pregnancy."

Dr. Thomas McElrath, MD, PhD

Practicing Maternal-Fetal Medicine Physician at Brigham and Women's Hospital. Vice President of Clinical Development at Mirvie.

REFERENCES:

Elovitz MA et al. Molecular subtyping of hypertensive disorders of pregnancy. Nature Comms (2025)

Fink DA et al. Trends in maternal mortality and severe maternal morbidity. JAMA Network Open (2023)

McElrath TF et al. Utility of the US Preventive Services Task Force for preeclampsia risk assessment and aspirin prophylaxis. JAMA Open Access (2025)

Moe AB et al. Low-dose aspirin adherence following objective cell-free RNA-based preeclampsia risk testing: a real-world survey study. medRxiv 2026.06.08.26355195 (2026)

Roberts J, et al. Care plan for individuals at risk for preeclampsia: shared approach to education, strategies for prevention, surveillance, and follow-up. Am J Obstet Gyn (2023)